240 related articles for article (PubMed ID: 17255281)
1. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
Wolff AC; Donehower RC; Carducci MK; Carducci MA; Brahmer JR; Zabelina Y; Bradley MO; Anthony FH; Swindell CS; Witman PA; Webb NL; Baker SD
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3589-97. PubMed ID: 14506145
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA
Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
[TBL] [Abstract][Full Text] [Related]
9. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
Verschraegen CF; Skubitz K; Daud A; Kudelka AP; Rabinowitz I; Allievi C; Eisenfeld A; Singer JW; Oldham FB
Cancer Chemother Pharmacol; 2009 Apr; 63(5):903-10. PubMed ID: 18682950
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
Chiorean EG; Malireddy S; Younger AE; Jones DR; Waddell MJ; Sloop MI; Yu M; Hall SD; Schneider B; Sweeney CJ
Cancer Chemother Pharmacol; 2010 Aug; 66(3):441-8. PubMed ID: 20091169
[TBL] [Abstract][Full Text] [Related]
14. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Boddy AV; Plummer ER; Todd R; Sludden J; Griffin M; Robson L; Cassidy J; Bissett D; Bernareggi A; Verrill MW; Calvert AH
Clin Cancer Res; 2005 Nov; 11(21):7834-40. PubMed ID: 16278406
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Kim TY; Kim DW; Chung JY; Shin SG; Kim SC; Heo DS; Kim NK; Bang YJ
Clin Cancer Res; 2004 Jun; 10(11):3708-16. PubMed ID: 15173077
[TBL] [Abstract][Full Text] [Related]
17. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Kalbakis K; Pappas P; Kouroussis C; Vamvakas L; Kalykaki A; Vardakis N; Nikolaidou M; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2008 Aug; 62(3):449-56. PubMed ID: 17960381
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
Bendell JC; Eder JP; Clark JW; Fidias P; Lynch TJ; Seiden MV; Ryan DP
Cancer; 2005 May; 103(9):1925-31. PubMed ID: 15772958
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM; Picus J; Wildi JD; Goodner SA; Creekmore AN; Gao F; Govindan R; Ellis MJ; Tan BR; Linette GP; Fu CJ; Pentikis HS; Zumbrun SC; Egorin MJ; Bellet RE
Cancer Chemother Pharmacol; 2009 Feb; 63(3):451-8. PubMed ID: 18414864
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]